🧬 Anti-Tau Monoclonal Antibody Trial Simulator

Extracellular Tau as a Druggable Antibody Target

Placeholder: why extracellular tau is targeted by monoclonal antibodies.

• N-terminal tau: Target epitope (Placeholder epitope note)
• 6: Tau isoforms (Placeholder isoform note)
• ELISA/SPR: Assay format (Placeholder assay note)
• 12: Candidate mAbs (Placeholder screening note)

Selecting the extracellular tau epitope

Placeholder: epitope mapping and antibody selection criteria.

Placeholder: key insight on extracellular tau targeting.

Blocking Cell-to-Cell Propagation of Pathological Tau

Placeholder: how antibody binding halts trans-synaptic tau spread.

• Trans-synaptic: Spread route (Placeholder route note)
• Sub-nM Kd: Binding affinity (Placeholder affinity note)
• ~70%: Uptake blocked (Placeholder uptake note)
• Tau-PS19 mice: Model system (Placeholder model note)

Neutralizing extracellular tau seeds

Placeholder: mechanism preventing seeding-competent tau uptake.

Placeholder: key insight on blocking propagation.

Dose-Escalation Cohorts in the Clinical Trial

Placeholder: low/medium/high dose cohort design rationale.

• 3: Cohorts (Placeholder cohort note)
• ~180: Participants (Placeholder enrollment note)
• Every 4 wk: Dosing interval (Placeholder schedule note)
• IV infusion: Route (Placeholder route note)

Cohort design and safety monitoring

Placeholder: dose-escalation and safety monitoring approach.

Placeholder: key insight on dosing cohorts.

Tau PET Imaging as a Response Biomarker

Placeholder: tau PET SUVR tracked longitudinally during treatment.

• 18F-flortaucipir: Tracer (Placeholder tracer note)
• 6 months: Scan interval (Placeholder interval note)
• 8 ROIs: Regions tracked (Placeholder ROI note)
• >15%: SUVR reduction goal (Placeholder target note)

Interpreting tau PET signal change

Placeholder: reading SUVR trends as treatment response.

Placeholder: key insight on PET monitoring.

Cognitive Endpoint Assessment and Trial Outcome

Placeholder: cognitive scales used to assess clinical benefit.

• CDR-SB: Primary scale (Placeholder scale note)
• ADAS-Cog: Secondary scale (Placeholder scale note)
• 18 months: Follow-up (Placeholder follow-up note)
• ~30% slowing: Effect size goal (Placeholder efficacy note)

Comparing treatment vs placebo trajectories

Placeholder: cognitive decline trajectory comparison.

Placeholder: key insight on cognitive endpoints.